• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Haemorrheological effects of prostaglandin E1 infusion in Raynaud's syndrome.前列腺素E1输注对雷诺综合征的血液流变学影响。
J Clin Pathol. 1984 Aug;37(8):870-3. doi: 10.1136/jcp.37.8.870.
2
A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome.一项关于前列腺素E1治疗雷诺氏综合征的多诊所、安慰剂对照、双盲研究。
Ann Rheum Dis. 1985 Nov;44(11):754-60. doi: 10.1136/ard.44.11.754.
3
Assessment of platelet function in patients with Raynaud's syndrome.雷诺综合征患者血小板功能的评估。
J Clin Pathol. 1984 Feb;37(2):182-7. doi: 10.1136/jcp.37.2.182.
4
Prostaglandin E1 in severe Raynaud's phenomenon.
Surgery. 1982 Dec;92(6):953-65.
5
Prostaglandin I2 and E1 and red cell deformability in raynaud's phenomenon and systemic sclerosis.前列腺素I2、E1与雷诺现象和系统性硬化症中的红细胞变形性
Br Med J (Clin Res Ed). 1981 Dec 12;283(6306):1608-9. doi: 10.1136/bmj.283.6306.1608-e.
6
Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.前列腺素E1对比安慰剂治疗进行性系统性硬化症伴严重雷诺现象患者的疗效评估
Minerva Cardioangiol. 1999 May;47(5):137-43.
7
Prostaglandin E1 vasospastic disease and thermography.前列腺素E1、血管痉挛性疾病与热成像
Ann Rheum Dis. 1985 Feb;44(2):73-8. doi: 10.1136/ard.44.2.73.
8
Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis.前列腺素E1输注治疗进行性系统性硬化症的血管功能不全
Ann Rheum Dis. 1981 Aug;40(4):350-4. doi: 10.1136/ard.40.4.350.
9
Use of prostaglandin E1 (lipo-PGE1) to treat Raynaud's phenomenon associated with connective tissue disease: thermographic and subjective assessment.使用前列腺素E1(脂微球载体前列腺素E1)治疗与结缔组织病相关的雷诺现象:热成像和主观评估。
J Pharm Pharmacol. 1992 May;44(5):442-4. doi: 10.1111/j.2042-7158.1992.tb03641.x.
10
Treatment of severe Raynaud's phenomenon with prostaglandin E1.
Ir J Med Sci. 1981 Jun;150(6):190-1. doi: 10.1007/BF02938232.

引用本文的文献

1
Nisoldipine in primary Raynaud's phenomenon.尼索地平治疗原发性雷诺现象。
Eur J Clin Pharmacol. 1987;33(1):27-30. doi: 10.1007/BF00610375.
2
Clinical and rheological effects of nifedipine in Raynaud's phenomenon.硝苯地平在雷诺现象中的临床及血液流变学效应
Br J Clin Pharmacol. 1986 Oct;22(4):449-54. doi: 10.1111/j.1365-2125.1986.tb02916.x.
3
The clinical importance of erythrocyte deformability, a hemorrheological parameter.红细胞变形性这一血液流变学参数的临床重要性。
Ann Hematol. 1992 Mar;64(3):113-22. doi: 10.1007/BF01697397.

本文引用的文献

1
BLOOD VISCOSITY AND RAYNAUD'S DISEASE.血液粘度与雷诺氏病
Lancet. 1965 May 22;1(7395):1086-8. doi: 10.1016/s0140-6736(65)92673-5.
2
Treatment of vasospastic disease with prostaglandin E1.用前列腺素E1治疗血管痉挛性疾病。
Br Med J. 1980 Oct 18;281(6247):1031-4. doi: 10.1136/bmj.281.6247.1031.
3
Haematological stress syndrome in atherosclerosis.动脉粥样硬化中的血液学应激综合征
J Clin Pathol. 1981 May;34(5):464-7. doi: 10.1136/jcp.34.5.464.
4
Serial study of C-reactive protein during infection in leukaemia.白血病感染期间C反应蛋白的系列研究
J Clin Pathol. 1981 Mar;34(3):263-6. doi: 10.1136/jcp.34.3.263.
5
Characterization of a leukocyte-derived endogenous mediator responsible for increased plasma fibrinogen.一种负责血浆纤维蛋白原增加的白细胞源性内源性介质的特性研究。
Ann N Y Acad Sci. 1982;389:338-53. doi: 10.1111/j.1749-6632.1982.tb22148.x.
6
Leukocytic pyrogen: a major mediator of the acute phase reaction.白细胞热原:急性期反应的主要介质。
Ann N Y Acad Sci. 1982;389:323-37. doi: 10.1111/j.1749-6632.1982.tb22147.x.
7
Effect of prostaglandins I2 and E1 on red cell deformability in patients with Raynaud's phenomenon and systemic sclerosis.前列腺素I2和E1对雷诺现象及系统性硬化症患者红细胞变形性的影响。
Br Med J (Clin Res Ed). 1981 Aug 1;283(6287):350. doi: 10.1136/bmj.283.6287.350.
8
Hyperviscosity and thrombotic changes in idiopathic and secondary Raynaud's syndrome.特发性和继发性雷诺综合征中的高黏滞血症和血栓形成变化
Br J Haematol. 1980 Aug;45(4):651-8. doi: 10.1111/j.1365-2141.1980.tb07188.x.
9
Erythrocyte filtrability measurement by the initial flow rate method.
Biorheology. 1983;20(2):199-211. doi: 10.3233/bir-1983-20209.
10
Immunoregulatory activity of metabolites of arachidonic acid and their role in inflammation.花生四烯酸代谢产物的免疫调节活性及其在炎症中的作用。
Br Med Bull. 1983 Jul;39(3):243-8. doi: 10.1093/oxfordjournals.bmb.a071827.

前列腺素E1输注对雷诺综合征的血液流变学影响。

Haemorrheological effects of prostaglandin E1 infusion in Raynaud's syndrome.

作者信息

Lucas G S, Simms M H, Caldwell N M, Alexander S J, Stuart J

出版信息

J Clin Pathol. 1984 Aug;37(8):870-3. doi: 10.1136/jcp.37.8.870.

DOI:10.1136/jcp.37.8.870
PMID:6540787
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC498884/
Abstract

Eighteen patients with severe Raynaud's syndrome had impaired deformability of erythrocytes, as measured by filtration through 5 micron diameter pores, compared with 19 healthy controls. The patients were given prostaglandin E1 (PGE1) or placebo by intravenous infusion for 72 h to assess the haemorrheological action of PGE1. Contrary to a previous report, PGE1 did not improve erythrocyte filterability. Infusion of PGE1 did, however, evoke an acute phase response with hyperproteinaemia and a leucocytosis and is a potentially important mediator of this stress response in patients with vascular disease.

摘要

与19名健康对照者相比,18名重度雷诺综合征患者的红细胞变形能力受损,这是通过红细胞经直径5微米的小孔滤过进行测量的。这些患者通过静脉输注给予前列腺素E1(PGE1)或安慰剂,持续72小时,以评估PGE1的血液流变学作用。与之前的一份报告相反,PGE1并未改善红细胞滤过率。然而,输注PGE1确实引发了急性期反应,伴有高蛋白血症和白细胞增多,并且是血管疾病患者这种应激反应的潜在重要介质。